NEWS

Press Release NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab

Press Release NeoImmuneTech Welcomes New Members to its Scientific Advisory Board

News Update NeoImmuneTech to Present at Cytokine-Based Drug Development Summit

Press Release FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the treatment of Glioblastoma Multiforme

Quarterly update QUARTERLY UPDATE (2Q 2022)

News Update Interest of Combining NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) with Pembrolizumab keeps Growing

News Update NeoImmuneTech to Display its Environmental, Social, and Governance Activities on its Corporate Website

Press Release A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

Press Release NeoImmuneTech to Present at Upcoming BIO International Convention

Press Release NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors